Janus kinase (JAK) inhibitor anti-inflammatories made by Pfizer, AbbVie and Eli Lilly for inflammatory diseases, such as rheumatoid arthritis and ulcerative colitis, have all received the strictest warnings added to their labels by the FDA, which cited risk of serious health issues and the possibility of death in patients age 50 and over.
Source: Drug Industry Daily